Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma

Fig. 3

Distribution of adverse events by grade and relatedness, according to study period. Of the 280 total AEs, 56.8 % occurred during the active period and 43.2 % during the placebo period. 254 (90.7 %) AEs were grade 1 and 26 (9.3 %) grade 2. While only 28 (10 %) AEs were classified as definitely or probably related, all 28 occurred during the active period, representing a statistically significant association between exposure to DAS181 and experiencing a definitely or probably related AE (8 discordant pairs, exact test p = 0.0039)

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us